成人癌症幸存者心功能障碍的预防与监测:美国临床肿瘤学会临床实践指南
该指南由多学科专家小组基于1996至2016年系统综述制定,纳入104项研究,针对成人癌症幸存者心功能障碍的预防与监测提出推荐。指南强调在开始治疗前对高风险患者讨论心功能障碍风险,某些高风险幸存者可从治疗期间的预防和筛查策略中获益,接受潜在心脏毒性治疗者应保持高度临床怀疑和低评估阈值,某些高风险幸存者完成治疗后可能需常规影像监测。
要点
- 开始治疗前,对心功能障碍风险足够高的个体应启动相关讨论。
- 某些高风险癌症幸存者可从癌症治疗期间实施的预防和筛查策略中获益。
- 接受潜在心脏毒性治疗者应保持高度临床怀疑和低心脏评估阈值。
核心结论
- 对心功能障碍风险足够高的个体,应在开始治疗前启动相关讨论。
- 某些高风险癌症幸存者可从癌症治疗期间实施的预防和筛查策略中获益。
- 接受潜在心脏毒性治疗者应保持高度临床怀疑和低心脏评估阈值。
- 某些高风险幸存者完成癌症治疗后可能需常规心脏影像监测,以便启动适当干预以阻止或甚至逆转心功能障碍进展。
研究设计与样本
- 由多学科代表组成的专家小组基于1996至2016年系统综述制定推荐,纳入Meta分析、随机临床试验、观察性研究和临床经验。
- 研究质量按研究设计采用既定方法评估,指南推荐部分采用Guidelines Into Decision Support方法制定。
- 共104项研究符合纳入标准,构成推荐的证据基础。
主要发现
- 共104项研究符合纳入标准,构成推荐的证据基础。
- 推荐强度基于证据质量、数量和一致性以及获益与危害的平衡。
关键数值与推荐
- 对心功能障碍风险足够高的个体,应在开始治疗前启动相关讨论。
- 某些高风险癌症幸存者可从癌症治疗期间实施的预防和筛查策略中获益。
- 接受潜在心脏毒性治疗者应保持高度临床怀疑和低心脏评估阈值。
- 某些高风险幸存者完成癌症治疗后可能需常规心脏影像监测,以便启动适当干预以阻止或甚至逆转心功能障碍进展。
临床怎么用
- 对心功能障碍风险足够高的个体,应在开始治疗前启动相关讨论。
- 某些高风险癌症幸存者可从癌症治疗期间实施的预防和筛查策略中获益。
- 接受潜在心脏毒性治疗者应保持高度临床怀疑和低心脏评估阈值。
- 某些高风险幸存者完成癌症治疗后可能需常规心脏影像监测,以便启动适当干预以阻止或甚至逆转心功能障碍进展。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the patient with cancer. The purpose of this effort was to develop recommendations for prevention and monitoring of cardiac dysfunction in survivors of adult-onset cancers. Methods Recommendations were developed by an expert panel with multidisciplinary representation using a systematic review (1996 to 2016) of meta-analyses, randomized clinical trials, observational studies, and clinical experience. Study quality was assessed using established methods, per study design. The guideline recommendations were crafted in part using the Guidelines Into Decision Support methodology. Results A total of 104 studies met eligibility criteria and compose the evidentiary basis for the recommendations. The strength of the recommendations in these guidelines is based on the quality, amount, and consistency of the evidence and the balance between benefits and harms. Recommendations It is important for health care providers to initiate the discussion regarding the potential for cardiac dysfunction in individuals in whom the risk is sufficiently high before beginning therapy. Certain higher risk populations of survivors of cancer may benefit from prevention and screening strategies implemented during cancer-directed therapies. Clinical suspicion for cardiac disease should be high and threshold for cardiac evaluation should be low in any survivor who has received potentially cardiotoxic therapy. For certain higher risk survivors of cancer, routine surveillance with cardiac imaging may be warranted after completion of cancer-directed therapy, so that appropriate interventions can be initiated to halt or even reverse the progression of cardiac dysfunction.
引用
- Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016. PMID: 27918725. doi:10.1200/JCO.2016.70.5400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。